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Epithelial-mesenchymal transition (EMT) has been shown to play a key role in embryogenesis and
cancer progression. We previously found that ﬁbronectin (FN) carrying O-GalNAc at a speciﬁc site
is selectively expressed in cancer and fetal cells/tissues, and termed oncofetal FN (onfFN). Here,
we show that (i) a newly-established monoclonal antibody against FN lacking the O-GalNAc, termed
normalFN (norFN), is useful for isolation of onfFN, (ii) onfFN, but not norFN, can induce EMT in
human lung carcinoma cells, (iii) onfFN has a synergistic effect with transforming growth factor
(TGF)b1 in EMT induction.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Numerous studies have demonstrated that carbohydrates ex-
pressed as glycosphingolipids (GSLs) or N- or O-linked glycans of
glycoproteins are correlated with cell phenotypes and are involved
in various cell functions such as cell adhesion, signal transduction,
growth, motility, and invasiveness [1–5]. In our previous studies,
we demonstrated the functional role of certain carbohydrate struc-
tures in epithelial-mesenchymal transition (EMT) [6–8].
The EMT process, was initially observed during early embryo-
genesis and organ formation [9,10], and was demonstrated to play
an essential role in disease development such as cancer progression
[11–14] and ﬁbrosis [15]. During the EMTprocess in cancer progres-
sion, transformed epithelial cells lose their apical-basal polarity and
change to an elongated ﬁbroblastic morphology. The cells also
display reduced expression of epithelial cell markers such as
E-cadherin (Ecad), concomitant with enhanced expression of
mesenchymal cell markers such as vimentin, N-cadherin (Ncad),
ﬁbronectin (FN), and enhanced cell motility [11–15]. FN is knownchemical Societies. Published by E
esenchymal transition; TGF,
oncofetal FN; norFN, normal
Hakomori).to exist inmultiple forms resulting fromalternative splicing and dif-
ferent glycosylation. The role of different FN isoforms in the EMT
process remains largely unknown, although the up-regulation of
FN has been widely used for the assessment of EMT induction. We
previously established mAb FDC6, using FN isolated from a human
cell line, HUH7 [16] as the immunogen. FDC6 reacts with FN in fetal
and cancer tissue and cells, but not with FN in normal adult tissue
and cells. FDC6-positive FN was therefore termed ‘‘oncofetal FN’’
(onfFN) and FDC6-negative FN as ‘‘normal FN’’ (norFN) [16,17].
Subsequent studies revealed that the epitope of FDC6 is based on
the addition of an O-glycan (GalNAca1-O-Ser/Thr or Galb1-3Gal
NAca1-O-Ser/Thr) to the Thr residue of the peptide sequence -Val-
Thr-His-Pro-Gly-Tyr-, which is located at the type III homology con-
nective segment (IIICS) domain of FN [17,18]. Our recent study [6]
on the role of onfFN in EMT process demonstrated that (i) the
expression of onfFN is strongly up-regulated during transforming
growth factor TGFb1-induced EMT process in human prostate cell
lines and (ii) the knock-down of UDP-N-acetylgalactosamine:
polypeptide N-acetylgalactosaminyltransferase (GalNAc-T)3 and
GalNAc-T6 with siRNA targeted to them, abolishes the enhanced
expression of onfFN without any change in total FN (tFN), and also
inhibits EMT induced with TGFb1. These results indicate the
functional role of onfFN in EMT induction.
In this study, we isolated onfFN and norFN using mAb FDC6 and
a newly established mAb against norFN, and examined theirlsevier B.V. All rights reserved.
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EMT induction using human non-small cell lung carcinoma
(NSCLC) cells.
2. Materials and methods
2.1. Cell culture
NSCLC cell lines, A549 and NCI-H358, were obtained from the
American Type Culture Collection (ATCC, Rockville, MD), and cul-
tured in RPMI 1640. Benign human hepatoma HUH7 cells [16],
which were donated by Dr. J. Sato (Okayama Univ., Japan), and
HUH7/T6 [6] were grown in DMEM. These media were supple-
mented with 10% FBS, penicillin (100 IU/ml) and streptomycin
(100 lg/ml) unless described otherwise. All cells were cultured in
a humidiﬁed chamber at 37 C in 5% CO2/95% air.
2.2. Reagents and antibodies
Antibodies used: anti-Ecad (IgG1; BD Biosciences, San Jose, CA),
anti-vimentin (IgM; Sigma, St. Louis, MO), anti-GAPDH (IgG1; Sig-
ma, St. Louis, MO), anti-total FN (EP5, IgG1; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), mAb FDC6 (IgG1) was established in our
laboratory [16], and mAb 2E11 (IgG1) for human GalNAc-T6 was
kindly donated by Drs. U. Mandel and H. Clausen (University of
Copenhagen, Denmark) [19]. Horseradish peroxidase (HRP)-
labeled goat anti-mouse IgG and -mouse IgM were from SouthernFig. 1. Production of mouse mAb speciﬁc for norFN and preparation of onfFN and norFN
the unbound fraction (norFN), and the bound and eluted fraction (onfFN) from FDC6-col
YKH1. (B) Separation of norFN and onfFN by immunoafﬁnity absorption. Aliquots (0.1
analyzed by Western blot using EP5, YKH1 and FDC6. (C) Production and secretion of on
total FN, norFN and onfFN were detected with mAbs 2E11, EP5, YKH1 and FDC6, respecBiotech (Birmingham, AL). Human plasma FN was from Sigma and
TGFb1 was from BD Biosciences. Other reagents were from Sigma,
unless described otherwise.
2.3. Production of mAb against norFN
The peptide, KTPFVTHPGYDTGNTCQC, consisting of 17 amino
acid sequence within the IIICS domain of FN and an additional
cysteine residue (C), was purchased from GenScript, (Piscataway,
NJ). The peptide was chemically linked with the imject malei-
mide-activated mcKLH (Thermo, Rockford, IL) through the C,
according to the manufacturer’s instructions. Balb/c (6–8 weeks
old) mice were intraperitoneally injected with 40 lg of the
KLH-conjugated peptide emulsiﬁed in TiterMax Gold adjuvant
(Titermax, Norcross, GA) twice at 2-week intervals. Seven days
after the second injection, the antibody tire in serum was deter-
mined by ELISA, using the peptide-conjugated with bovine serum
albumin (BSA). The mice that showed high antibody titer were gi-
ven the last boost with 40 lg of FDC6-negative FN without adju-
vant. Three days later, splenocytes were collected and fused with
SP2/0 mouse myeloma cells and hybridomas were selected, as
previously described [20]. Antibody production was screened by
ELISA using total FN. After cloning by limiting-dilution, YKH1
clone was established. Its isotype was determined with IsoStrips
(Boehringer Mannheim, Indianapolis, IN). All procedures with
mice were approved by the Institutional Animal Care and Use
Committee (IACUC).using the mAb. (A) Speciﬁcity of mAb YKH1 was determined by Western blot using
umn. Aliquots (0.1 lg protein) of each FN were analyzed with mAbs EP5, FDC6, and
lg protein) of tFN, norFN (unbound to FDC6) and onfFN (unbound to YKH1) were
fFN in HUH7 cells overexpressing GalNAc-T6 (HUH7/T6). Expression of GalNAc-T6,
tively, using cell lysates and culture supernatants.
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Total FN was prepared from the culture supernatant of HUH7/T6
cells by gelatin–agarose (Sigma) column chromatography, as de-
scribed previously [17,18,21] and were further separated into
onfFN and norFN using mAbs YKH1 and FDC6, respectively. Each
mAb was puriﬁed with proteinG resin (GeneScript), according to
the vendor’s instructions. Each puriﬁed mAb, 1.5 mg, was cova-
lently bound to 1.5 mL protein A/G PLUS-Agarose slurry (Santa Cruz
Biotechnology), using disuccinimidyl suberate (Thermo, Rockford,
IL), following the vendor’s instruction. After equilibration with
50 mM Tris buffer, pH 8.0, total FN (1 mg each) was added to the
beads. After mixing overnight at 4 C, unbound FN from FDC6-
bound beads and YKH1-bound beads were collected and used as
norFN and onfFN, respectively. Thus, onfFN and norFN were en-
riched at 8- and 1.3-fold, respectively. In some experiments, FN
bound to FDC6-beads was eluted with low pH buffer and used as
onfFN. Unbound fraction resulting from consecutive absorptions
to FDC6 and to YKH1 did not show detectable amount of FN, which
was estimated with EP5 by Western blot.
2.5. Analysis of EMT induction
For EMT induction with TGFb1, A549 cells (1  105/well) and
NCI-H358 (3  105/well) were cultured in 6-well plates overnight,
and the cells were treated with TGFb1 (5 ng/mL), and cultured for
72 h. For EMT inductionwith FN, 6-well plates were incubated with
plasma FN (pFN), total FN, norFN, onfFN or BSA at 50 lg/ml in D-
PBS, at 4 C overnight, and then washed with D-PBS. A549 cellsFig. 2. Characterization of FN up-regulated during TGFb1-induced EMT in human lung
treated as described in M&M. Cell lysates (10 lg protein) were analyzed by SDS/PAGE an
FDC6, respectively; Together with GAPDH used as loading control. Representative results
and relative intensities are shown as mean ± SD (B and D). ns: not signiﬁcant; ⁄⁄p 6 0.00(1  105) and NCI-H358 (3  105) were seeded on the coated well
and incubated for 72 h. After taking photos of these cells, cell ly-
sates were prepared, protein concentration was determined, and
10 lg protein was analyzed by Western blot, as described previ-
ously [8,20,22–24]. Cell motility was determined by two proce-
dures: i) Phagokinetic gold sol assay, as previously described
[22,23]. (ii) Wound assay, as previously described [6]. Brieﬂy,
A549 (2  105) and NCI-H358 (5  105) were seeded or treated as
described above, and scratches were made. After taking photos of
the scratches, the cells were incubated in culture medium for 18 h.
3. Results and discussion
3.1. Establishing a new hybridoma for norFN and preparation of onfFN
and norFN
Our previous study that showed the functional role of onfFN in
TGFb1-induced EMT [6] implicated that onfFN, but not norFN, may
have the activity to induce EMT. For efﬁcient isolation of onfFN, we
established a hybridoma that produces mAb against norFN, by
immunizing KLH-conjugated peptide that contains Val-Thr-His-
Pro-Gly-Tyr, whose Thr is O-glycosylated in onfFN.
Only one out of 60 clones positive for the peptide showed selec-
tive binding to norFN over onfFN (Fig. 1A). This clone was named
YKH1. The protein A/G agarose-bound with YKH1 removed norFN
to enrich onfFN, while FDC6 removed onfFN to enrich norFN
(Fig. 1B).
Our previous study [6] indicated that HUH7 cells produce more
norFN than onfFN. In order to make the cells secrete more onfFN,carcinoma cells. A549 cells (A and B) and NCI-H358 (C and D) were cultured and
d Western blot. Total FN, norFN and onfFN were detected with mAbs EP5, YKH1 and
from triplicate experiments are shown (A and C). Signal intensities were normalized,
5.
Fig. 3. Analysis of EMT induction with total FN. Plates were coated with BSA, plasma FN (pFN), or total FN (tFN), and the cells were seeded on the coated plates as described in
M&M. TGFb1 treatment was used as a positive control. (I) For morphology changes, photos were taken by phase-contrast microscopy (Nikon) at 80 magniﬁcation. (II)
Expression level of epithelial vs. mesenchymal cell markers were analyzed byWestern blot using cell lysates (10 lg protein) of A549 (A, C, E and G) and NCI-H358 cells (B, D, F
and H). Representative results from triplicate experiments are shown (A and B). Signal intensities were normalized, and relative intensities are shown as mean ± SD for Ecad
(C and D), Ncad (E and F) and vimentin (G and H). ns: not signiﬁcant; ⁄P 6 0.05; ⁄⁄P 6 0.005.
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Fig. 4. Analysis of EMT induction with onfFN. Plates were coated with norFN or onfFN and A549 and NCI-H358 cells were seeded as described in M&M. TGFb1 treatment was
used as a positive control. (I) Cell morphology changes were analyzed as described in Fig. 3. (II) Expression level of epithelial vs. mesenchymal cell markers were analyzed as
described in Fig. 3. Representative results from triplicate experiments are shown (A and B). Signal intensities were normalized, and relative intensities are shown as
mean ± SD for Ecad (C and D), Ncad (E and F) and vimentin (G and H). ns: not signiﬁcant; ⁄P 6 0.05; ⁄⁄P 6 0.005; ⁄⁄⁄P 6 0.001. (III) Cell motility changes induced with the
treatments were assessed by phagokinetic assay (Top of A and B) and wound assay (Bottom of A and B). Phagokinetic assay was performed as described in M&M. Photos of
track areas of 30 cells were taken; Representative photos are presented. Cleared areas on gold sol were measured, analyzed using the Scion Image program as squared pixels,
and are shown as mean ± SD (C and E). n.s.: not signiﬁcant; ⁄P 6 0.05; ⁄⁄P 6 0.005. The wound assay was performed as described in M&M. Pictures of the wounds at the
marked position were taken at 0 h and after an 18 h incubation. Bold lines show the original edge of the wounds at 0 h. Results are expressed as mean ± SD of percent of the
initial wound area remaining open, analyzed using the Scion Image program (D and F). ns: not signiﬁcant; ⁄P 6 0.05; ⁄⁄P 6 0.005.
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Fig. 4 (continued)
1818 Y. Ding et al. / FEBS Letters 586 (2012) 1813–1820we transfected human GalNAc-T6 cDNA and established HUH7/T6
cells, as previously described [6]. HUH7/T6 cells produced more
onfFN and less norFN than HUH7 cells, which was determined both
with cell lysates and culture supernatants (Fig. 1C). Although accu-
mulating evidence supports the importance of site-speciﬁc O-gly-
cosylation [25–27], peptide motifs for O-glycosylation and
substrate speciﬁcity for each GalNAc-T have not been elucidated.
This result supports the previous works showing the involvement
of GalNAc-T6 in biosynthesis of onfFN [26,28].
3.2. Enhanced expression of onfFN during TGFb1-induced EMT in
human lung cell lines, A549 and NCI-H358
Consistent with the previous result with prostate cells [6], the
FN expressed in TGFb1-treated A549 and NCI-H358 cells was
mainly onfFN, and norFN which were detected with YKH1 re-
mained at a similar level (Fig. 2). These results suggest that up-reg-
ulated FN during TGFb1-induced EMT belongs mainly to onfFN,
although analysis with various other cell lines will need to be per-
formed to generalize the ﬁndings.
3.3. EMT induction with onfFN in A549 and NCI-H358 cells
A functional role of onfFN biosynthesis during EMT was shown
in our previous study with prostate cells [6], which implicated that
onfFN has the activity to induce EMT. Preliminary studies using to-
tal FN showed higher EMT inducing activity with human NSCLCs
than with the prostate cells (data not shown), thus further studies
were performed with the lung cell lines, A549 and NCI-H358. The
cells were seeded on the plates coated with total FN, human pFN
or BSA. The cells seeded on the non-coated plates were treated
with TGFb1 and used as a positive control. Signiﬁcant changes in
morphology similar to TGFb1-treated cells were observed with
both cell lines when seeded on total FN, while the cells seeded
on pFN or BSA did not show any signiﬁcant changes (Fig. 3I).EMT induction was also detected by the reduced expression of epi-
thelial cell marker, Ecad, and the enhanced expression of mesen-
chymal markers, Ncad and vimentin (Fig. 3II); although EMT
inducing activity of total FN was lower than that of TGFb1.
Next, we isolated onfFN and norFN using FDC6 and YKH1
(Fig. 1B), and analyzed their ability to induce EMT. TGFb1-treated
cells and the cells in onfFN-coated wells displayed an elongated
shape, and a decrease in cell-cell contact in both cell lines. The cells
in norFN-coated wells did not show these changes (Fig. 4I). In addi-
tion, onfFN induced the down-regulation of Ecad concomitant with
the up-regulation of Ncad and vimentin, similar to TGFb1, while
norFN did not induce detectable changes (Fig. 4II). The different
activity of onfFN and norFN is also demonstrated in cell motility,
which was assessed by two assays: phagokinetic cell motility assay
on gold-sol and wound-scratch assay (Fig. 4III). In addition, the
EMT induction with onfFN was blocked by pre-incubation of the
onfFN-coated plates with mAb FDC6 (Supplementary Fig. 1).
Other types of FN isoforms are known to be produced through
alternative splicing; Some are at the IIICS domain [29–31], while
others consist of two different complete type III repeats, extra do-
main (ED)-A and -B [32]. Whether onfFN contains ED-A or ED-B, re-
mains to be studied. Although mAb FDC6 has been used clinically
to distinguish fetal and adult cells, the functional role of the O-gly-
cosylation to form onfFN was not fully investigated. As far as we
know, this is the ﬁrst report that shows isolated onfFN and norFN
have different biological functions.
Recently, it was reported that O-glycosylation of FN through
GalNAc-T6 is associated with EMT-like process in human breast
cancer cells [33], although the O-glycosylated FN was not exam-
ined for FDC6-binding.
3.4. Synergistic effect of TGFb1 and onfFN in EMT induction
We tested the possibility that onfFN and TGFb1 work synergis-
tically in EMT induction. EMT induction with TGFb1 in these cell
Fig. 5. Synergistic effect between onfFN and TGFb1 in EMT induction. Plates were coated with norFN or onfFN and A549 and NCI-H358 cells were seeded on the plates as
described at M&M. After 2 h incubation, TGFb1(0.5 ng/ml) were added and the cells were incubated for 70 h. (I) Cell morphology changes were detected as described in Fig. 3.
(II) Expression level of epithelial vs. mesenchymal cell markers were analyzed as described in Fig 3. Representative results from triplicate experiments are shown (A and B).
The folds of the change of Ecad (C and D), Ncad (E and F) and vimentin (G and H) expression following the stimulation are shown as mean ± SD. ns: not signiﬁcant; ⁄P 6 0.05;
⁄⁄P 6 0.005; ⁄⁄⁄P 6 0.001.
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5 ng/ml (Fig. 2–4), some at 2 and 1 ng/ml (data not shown), and
EMT induction was not clearly detected at 0.5 ng/ml (Fig. 5I and
II). However, addition of TGFb1 at 0.5 ng/ml to the cells seeded
on onfFN demonstrated synergistic effect in EMT induction, which
was assessed by cell morphology change (Fig. 5I), and by the
expression of EMT marker molecules (Fig. 5II). Such effect of TGFb1
was not detected with the cells seeded on norFN, as expected. The
synergistic effect between onfFN and TGFb1 observed here impli-
cates an interesting possibility that onfFN, secreted from the cells
that underwent EMT and incorporated into extracellular matrix
surrounding the carcinoma cells, facilitates EMT induction with
TGFb1 at low concentration, which is not enough to fully induce
EMT alone. Co-regulatory function of FN variants with TGFb1 has
also been reported in phenotype change of mesenchymal/myoﬁ-
broblasts [34].
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